Company: NOTV
Filing Date: 2025-01-23
Form Type: DEF 14A
Source: 0001628280-25-002250
Chunk: 1

Company: Inotiv, Inc.
Filing Date: 2025-01-23
Form: DEF 14A
Chunk 1
---
 diet, bedding and enrichment product lines was offset by softer demand for small animal models, reflecting the broader slowdown in biopharma spending. Nevertheless, we continued to drive operational efficiency, seeking to optimize our production network and transportation infrastructure. As some of these efficiencies are expected to yield further benefits in 2025, we are also implementing additional programs designed to enhance margins.

DSA revenues declined year-over-year; however, facilities and service lines expanded or introduced in recent years continued to demonstrate growth, and we expect this momentum to carry forward as the biopharmaceutical industry refocuses on earlier-stage assets.

We managed general and administrative spending aggressively over the past fiscal year, including substantial reductions in certain third-party expenses . Simultaneously, we continued to invest in areas such as sales capabilities and human capital to enhance scientific excellence and customer service delivery.

During fiscal 2024, we announced several key leadership appointments that strengthened our governance and compliance framework. Terry Coelho and Mike Harrington were elected as new members of the Board of Directors, bringing extensive expertise in the pharmaceutical and health care industries to further support our strategic objectives. Additionally, Matt Neff was appointed as the new Chairman of the Board, reflecting his commitment to advancing Inotiv’s vision. To further enhance our compliance function, Andrea Castetter was appointed as Chief Compliance Officer, tasked with driving the development and implementation of a robust compliance program, focusing on adherence to regulatory standards, fostering a culture of accountability across the organization, and proactively identifying and mitigating compliance risks to support Inotiv’s long-term success. These actions reaffirm our dedication to effective governance and high standards of corporate responsibility.

While fiscal 2024 was a demanding year, we addressed many of the challenges head-on, improving operational efficiency and reinforcing our ability to meet customer needs. Our sustained focus on growth and innovation earned us recognition as a Deloitte Fast 500 company for the second consecutive year.

We are confident that our long-term strategy, combined with the commitment and dedication of our employees, will continue to drive value creation for our customers, shareholders, and team members in the years to come. Furthermore, the recent appointment of key leadership roles underscores our commitment to strengthening governance and enhancing the compliance function, fostering a culture of accountability and excellence.

Sincerely,

#### Robert W. Leasure, Jr
#### .

President and Chief Executive Officer

NOTICE OF ANNUAL MEETING OF SHAREHOLDERS OF INOTIV, INC.

DATE: March 13, 2025

TIME: 10:00 a